Mifeprex Helps Slow Decline In Abortion Providers
Guttmacher Institute announced that use of Mifeprex (the brand name for mifepristone) for early medication abortion increased substantially between 2000 and 2005. According to the report, approximately 78-81% of clinics now offer Mifeprex.
The report also found that more than half of all known abortion providers are offering Mifeprex, a 70% increase from the first half of 2001. Additionally, these findings show that the increased number of Mifeprex providers has helped to slow the overall decline in abortion providers. Since FDA approval of Mifeprex in September 2000, more than 840,000 women in the United States have chosen Mifeprex as a safe and effective, private option for ending early pregnancy.
Nearly 90% of abortions in the U.S. occur during the first trimester. In more recent years women having an abortion are able to do so earlier and earlier in the first trimester. According to Guttmacher, the proportion of providers offering very early medication or surgical abortions grew from 7% in 1993 to 40% in 2005. Mifeprex allows women to act early, up to 7 weeks from the beginning of their last menstrual period. Currently, more than six in 10 abortions occur within the first 8 weeks of pregnancy.
Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following Mifeprex use. No causal relationship between the use of Mifeprex and misoprostol and these events has been established.
A high index of suspicion is needed to rule out serious and rarely fatal infections (e.g. Clostridium sordellii) and sepsis that can present without fever, bacteremia or significant findings on a pelvic exam, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise.